APA (7th ed.) Citation

Schönfelder, K., Möhlendick, B., Eisenberger, U., Kribben, A., Siffert, W., Heinemann, F. M., . . . Friebus-Kardash, J. Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients. MDPI AG.

Chicago Style (17th ed.) Citation

Schönfelder, Kristina, Birte Möhlendick, Ute Eisenberger, Andreas Kribben, Winfried Siffert, Falko M. Heinemann, Anja Gäckler, Benjamin Wilde, and Justa Friebus-Kardash. Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection Among CYP3A5-Expressing Renal Transplant Patients. MDPI AG.

MLA (9th ed.) Citation

Schönfelder, Kristina, et al. Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection Among CYP3A5-Expressing Renal Transplant Patients. MDPI AG.